Drs. Falk and Jennette authored the studies published in the New England Journal of Medicine.
Dr. Ron Falk, Director of the UNC Kidney Center, spoke with a reporter about two studies recently published in the New England Journal of Medicine comparing the use of rituximab with cyclophosphamide (cytoxan) in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Both trials showed that rituximab was effective in inducing a remission, compared with intravenous cytoxan or oral cyclophosphamide. Drs. Falk and Jennette authored an editorial on the subject that was published in the July 15 issue of the journal.